Search Medical Condition
Please enter condition
Please choose location from dropdown

Bradenton, Florida Clinical Trials

A listing of Bradenton, Florida clinical trials actively recruiting patient volunteers.

Found (162) clinical trials

Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer

This is a first-in-human study of AZD9833 monotherapy (Parts A and B) and AZD9833 in combination with palbociclib (Parts C and D) in women with ER Positive HER2 Negative advanced breast cancer that is not amenable to treatment with curative intent. Parts A and C of the study allow for …

Phase

5.43 miles

Learn More »

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies

This is a Phase 1, open-label, multicenter, dose escalation study of intratumoral injections of mRNA-2752 alone and in combination with intravenously administered immune checkpoint blockade therapy in patients with histologically confirmed advanced or metastatic solid tumor malignancies or lymphoma. The study consists of 2 dose escalation and dose confirmation parts …

Phase

5.43 miles

Learn More »

A Study of JNJ-64619178 an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors NHL and Lower Risk MDS

The study is designed to determine the maximum tolerated dose (MTD) of JNJ-64619178, and to select a dose(s) and regimen(s) that may be used in future clinical development. Study evaluations will include safety, pharmacokinetics, biomarkers and efficacy evaluations (Disease Assessments). Adverse events will be evaluated throughout the study. The study …

Phase

5.43 miles

Learn More »

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

This is an open-label, Phase I-II, first-in-human (FIH) study for A166 as monotherapy in HER2-expressing patients who progressed on or did not respond to available standard therapies. Patients enrolled in this Phase III study must have documented HER2 positivity defined as positive on in situ hybridization (ISH) or next-generation sequencing …

Phase

5.43 miles

Learn More »

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced gynecological solid tumor (Phase 2).

Phase

5.43 miles

Learn More »

RBN-2397 an Oral PARP7 Inhibitor in Patients With Solid Tumors FIH MAD Study

This is a first-in-human, Phase 1, multi-center, open-label, dose-escalation study to: Evaluate the safety profile and MTD of RBN-2397 administered orally and establish the RBN-2397 dose(s) and schedule(s) recommended for further investigation in Phase 2 Characterize the PK profile of RBN-2397 Identify preliminary antitumor activity. Biomarkers and their correlation with …

Phase

5.43 miles

Learn More »

A Study of CC-99712 a BCMA Antibody-Drug Conjugate in Subjects With Relapsed and Refractory Multiple Myeloma

Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in subjects with relapsed and refractory multiple myeloma (MM). The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of CC-99712, …

Phase

5.43 miles

Learn More »

Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

This study will evaluate the safety and tolerability of PMD-026 using an accelerated titration design to define the MTD in metastatic breast cancer, followed by an expansion at the RP2D in triple negative breast cancer. All patients will receive daily oral doses of PMD-026 until either disease progression or unacceptable …

Phase

5.43 miles

Learn More »

An Open-label Phase II Study of AZD4635 in Patients With Prostate Cancer

This is an open-label Phase II modular study in patients with prostate cancer which will assess safety, efficacy, and tolerability of AZD4635 in combination with other therapeutic agents in different treatment arm (referred to as modules). Combinations to be studied include: 1) Module 1: AZD4635 plus durvalumab; 2) Module 2: …

Phase

5.43 miles

Learn More »

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

BT5528 consists of a bicyclic peptide (Bicycle) which binds to EphA2, and is covalently attached to a spacer and a protease cleavable peptide linker attached to MMAE. The Phase I/II multi-center, open-label trial will evaluate BT5528 administered once-weekly as a single agent and in combination with nivolumab. The Phase I …

Phase

5.43 miles

Learn More »